Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous study examined a number of methamphetamine (METH)/phencyclidine (
PCP
)-reactive tags in rat brain, using a serial analysis of gene expression. Among human homologous genes, which matched METH/
PCP
-reactive tags, three human genes were identified: phosphoprotein enriched in astrocyte 15 (PEA15), ectonucleoside triphosphate diphosphohydrolase 4 (ENTPD4), and
growth arrest-specific 2 like 1
(
GAS2L1
), which are localized in the chromosome 1q21.1, 8p21.3, and 22q12.2, respectively. We postulated that these genes are plausible candidate genes that play a role in pathogenesis for schizophrenia. Using tagging single-nucleotide polymorphisms (SNPs), we performed a case-control comparison for three SNPs in the PEA15 gene, and six SNPs in the
GAS2L1
gene in a sample set of subjects (240 schizophrenia patients and 286 control subjects). Twelve SNPs in the ENTPD4 gene were analyzed in a subset of subjects (94 schizophrenia patients and 94 control subjects). No single SNP displayed a significant difference regarding the allelic frequency or genotypic distribution between the affected cases and controls for any of the genes examined. There was neither a significant difference in the frequency of three marker haplotype in the PEA15 gene or of six marker haplotype in the
GAS2L1
gene between the cases and controls. The present study fails to provide evidence for the contribution of PEA15, ENTPD4, and
GAS2L1
genes to the etiology of schizophrenia in the Japanese population.
...
PMID:An association study on polymorphisms in the PEA15, ENTPD4, and GAS2L1 genes and schizophrenia. 2053 21